年轻慢阻肺及慢阻肺前期患者的治疗试验:是时候向前推进了
本文提出应在「年轻」慢阻肺患者(20-50岁)和慢阻肺前期(pre-COPD)人群中开展治疗性随机对照试验(RCT),以延缓疾病进展。文章详述了RCT设计方法,包括潜在结局指标(肺功能、患者报告结局、急性加重、肺部影像、死亡率及复合终点)以及统计学把握度、治疗时长和试验结构(平台、篮式、伞式试验)等关键设计要素。
要点
- 建议在20-50岁年轻慢阻肺患者及任何年龄的pre-COPD人群中开展RCT。
- pre-CERD定义为有呼吸道症状伴或不伴结构和/或功能异常,但无气流受限,可能随时间出现持续气流受限。
- RCT设计需考虑肺功能、患者报告结局、急性加重、影像、死亡及复合终点等结局。
核心结论
- 需要在年轻慢阻肺患者和慢阻肺前期患者中开展治疗性RCT以延缓疾病进展。
研究设计与样本
- 本文为概念性提出与综述,未报告具体研究样本。
主要发现
- 提出「年轻」慢阻肺患者年龄范围为20-50岁,因肺脏生长至约20岁,约50岁开始衰老。
- pre-CERD定义为任何年龄个体有呼吸道症状伴或不伴结构和/或功能异常,无气流受限,可能随时间出现持续气流受限。
- 排除婴幼儿、青少年及老年人,因生理背景独特或既往RCT已有代表。
关键数值与推荐
- 年轻慢阻肺患者年龄范围为20-50岁。
- pre-CERD为有呼吸道症状伴或不伴结构和/或功能异常,无气流受限,可能发展为持续气流受限。
临床怎么用
- 建议针对年轻慢阻肺患者和任何年龄的pre-CERD患者设计RCT,以延缓疾病进展。
- RCT设计可考虑肺功能、患者报告结局、急性加重、肺部影像、死亡及复合终点等结局。
- 需关注统计学把握度与分析、治疗时长及试验结构(平台、篮式、伞式试验)。
局限性
- 本文未报告具体研究数据或样本量。
- 讨论排除了婴幼儿、青少年及老年人,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: "young" individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at approximately 50 years, we consider "young" patients with COPD those patients in the age range of 20-50 years. Pre-COPD relates to individuals of any age who have respiratory symptoms with or without structural and/or functional abnormalities, in the absence of airflow limitation, and who may develop persistent airflow limitation over time. We exclude from the current discussion infants and adolescents because of their unique physiological context and COPD in older adults given their representation in prior randomized controlled trials (RCTs). We highlight the need of RCTs focused on COPD in young patients or pre-COPD to reduce disease progression, providing innovative approaches to identifying and engaging potential study subjects. We detail approaches to RCT design, including potential outcomes such as lung function, patient-reported outcomes, exacerbations, lung imaging, mortality, and composite endpoints. We critically review study design components such as statistical powering and analysis, duration of study treatment, and formats to trial structure, including platform, basket, and umbrella trials. We provide a call to action for treatment RCTs in 1) young adults with COPD and 2) those with pre-COPD at any age.
引用
- Martinez FJ, Agusti A, Celli BR, et al. Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. Am J Respir Crit Care Med. 2022. PMID: 34672872. doi:10.1164/rccm.202107-1663SO
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。